---
title: "Theravance Biopharma, Inc. (TBPH.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/TBPH.US.md"
symbol: "TBPH.US"
name: "Theravance Biopharma, Inc."
industry: "Pharmaceuticals"
datetime: "2026-05-22T00:03:29.690Z"
locales:
  - [en](https://longbridge.com/en/quote/TBPH.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/TBPH.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/TBPH.US.md)
---

# Theravance Biopharma, Inc. (TBPH.US)

## Company Overview

Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |
| Website | [www.theravance.com](https://www.theravance.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-21T04:30:16.000Z

**Overall: B (0.27)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 26 / 190 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Growth - Stocks whose main business is in the growth stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 68.20% |  |
| Net Profit YoY | 296.36% |  |
| P/B Ratio | 2.94 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 853202232.75 |  |
| Revenue | 109775000.00 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 50.17% | A |
| Profit Margin | 104.34% | A |
| Gross Margin | 67.07% | A |
| Revenue YoY | 68.20% | A |
| Net Profit YoY | 296.36% | A |
| Total Assets YoY | 37.47% | A |
| Net Assets YoY | 75.07% | A |
| Cash Flow Margin | 234.66% | A |
| OCF YoY | 68.20% | A |
| Turnover | 0.27 | D |
| Gearing Ratio | 38.47% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Theravance Biopharma, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "68.20%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "296.36%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "2.94",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "853202232.75",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "109775000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "50.17%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "104.34%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "67.07%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "68.20%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "296.36%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "37.47%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "75.07%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "234.66%",
          "rating": "A"
        },
        {
          "name": "OCF YoY",
          "value": "68.20%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.27",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "38.47%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 7.45 | 9/190 | 53.76 | 32.84 | 8.16 |
| PB | 2.94 | 112/190 | 4.07 | 3.23 | 2.95 |
| PS (TTM) | 7.77 | 109/190 | 11.80 | 9.00 | 8.10 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Cormedix (CRMD.US) | A | A | B | C | B | A |
| 02 | Eli Lilly (LLY.US) | A | A | B | D | B | B |
| 03 | ROCHE HOLDINGS AG (RHHVF.US) | A | B | B | D | B | B |
| 04 | Roche (RHHBY.US) | A | B | B | D | B | B |
| 05 | AstraZeneca (AZN.US) | A | B | C | D | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-08T04:00:00.000Z

Total Analysts: **6**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 3 | 50% |
| Hold | 3 | 50% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 16.34 |
| Highest Target | 21.00 |
| Lowest Target | 15.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/TBPH.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/TBPH.US/norm.md)
- [Related News](https://longbridge.com/en/quote/TBPH.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/TBPH.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**